Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001860 · ClinicalTrials.gov registry record · Phase 2
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
A Phase 2 study of Acromegaly and Pituitary Neoplasm, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00001860: Completed Phase 2 study of Acromegaly and Pituitary Neoplasm, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00001860 is a Phase 2 study of Acromegaly and Pituitary Neoplasm that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 5 participants, below the 101-participant average among 13 other Acromegaly trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001860, a Phase 2 study of Acromegaly and Pituitary Neoplasm, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients with macroadenomas. The primary goal is to normalize insulin-like growth factor-1 (IGF-1) levels. Secondary goals are to compare Sandostatin LAR® (Registered Trademark) Depot treatment and transsphenoidal surgery to achieve the following goals: suppress growth hormone levels to less than or equal to 2.5 ng/mL, relieve the clinical signs and symptoms of acromegaly, reduce the size of the macroadenomas, produce few side effects, assess the prognostic value of baseline pituitary adenoma size, extension and baseline growth hormone level on post-treatment growth hormone and IGF-1 levels, and assess the resource utilization of each treatment type.
Conditions Studied
Interventions
- DRUG Sandostatin LAR Depot versus transsphenoidal surgery
Study Locations (1)
Maryland
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 1999-08 |
| Est. Completion | 2002-07 |
| Phase | Phase 2 |
What the finished NCT00001860 record still lists
NCT00001860 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 101-participant average among 13 other Acromegaly trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Acromegaly appearing as the primary indexed condition, and to 1 intervention - of which Sandostatin LAR Depot versus transsphenoidal surgery is the first listed.
NCT00001860 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001860 about?
NCT00001860 is a clinical study titled "Sandostatin LAR Depot vs. Surgery for Treating Acromegaly". The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients with macroadenomas. The primary goal is to normalize insulin-like growth factor-1 (IGF-1) levels. Secondary goals are to compa...
What is the current status of trial NCT00001860?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 1999-08. Estimated completion is 2002-07.
What conditions does trial NCT00001860 study?
This clinical trial studies the following conditions: Acromegaly, Pituitary Neoplasm.
What interventions are being tested in trial NCT00001860?
The interventions under investigation include: Sandostatin LAR Depot versus transsphenoidal surgery (DRUG).
Who is sponsoring clinical trial NCT00001860?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001860 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acromegaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001860's enrollment target sits among peer trials
5 14th of 13 the lowest of 13 other Acromegaly trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acromegaly trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
RECRUITING · Phase 3
-
Diet in the Management of Acromegaly
RECRUITING · NA
-
Study of MAR002 in Healthy Men
RECRUITING · Phase 1
-
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia